Welcome to our dedicated page for Akari Therapeutics Plc SEC filings (Ticker: AKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Akari Therapeutics plc filings document the regulatory record of an England and Wales biotechnology issuer whose ordinary shares trade on Nasdaq only in connection with American Depositary Shares. The company’s SEC disclosures cover S-1 registration statements, 8-K material-event reports, proxy materials, and shareholder voting results tied to its ADS and ordinary-share structure.
Akari’s filings describe securities offerings, private placements, warrants, note exchanges, ADS ratio matters, Nasdaq listing-rule approvals, and amendments affecting share capital. Proxy and meeting materials also document U.K. public-company governance, quorum and voting mechanics, security-holder rights, and approvals related to the company’s capital structure.
Akari Therapeutics reported third-quarter 2025 results marked by a larger loss and an asset write-down. Net loss was $6.4 million for Q3 and $12.0 million for the nine months ended September 30, 2025, driven in part by a $5.18 million impairment of the PHP‑303 intangible as the company reprioritized to its ADC platform.
Cash was $2.5 million as of September 30, 2025, with an accumulated deficit of $259.3 million. Management stated these factors raise substantial doubt about the company’s ability to continue as a going concern and is evaluating financing alternatives. Total assets were $45.4 million, including $34.0 million of IPR&D (AKTX‑101), while shareholders’ equity was $22.7 million. Ordinary Shares outstanding were 71,479,461,523 as of November 13, 2025.
Akari Therapeutics (AKTX) calls a Dec 15, 2025 general meeting to seek approval for the exercisability of warrants to purchase an aggregate 6,375,000 ADSs under Nasdaq Listing Rule 5635(d), and to implement a capital reorganization.
Resolution 1 covers Series E and F Investor Warrants at an $0.98 exercise price and Placement Agent Warrants at $1.00, with potential gross cash proceeds of approximately $6.25 million if fully exercised for cash. Warrants include a 4.99% (or 9.99%) beneficial ownership cap.
Resolutions 2–6 propose: sub‑division reducing ordinary share nominal value from $0.0001 to $0.000000005 and creation of 1,429,517,750,998,477 Deferred Shares; director authority to allot up to $3,000 nominal (through June 30, 2030); approval to buy back and cancel all Deferred Shares for $0.01; disapplication of pre‑emption rights (through June 30, 2030); and adoption of New Articles. The board unanimously recommends voting FOR all proposals.
Record time for ordinary shareholders is 6:30 p.m. London on Dec 11, 2025; ADS voting instructions are due by Dec 4, 2025.
Akari Therapeutics (AKTX) reported an insider equity grant by its Interim CFO. On 11/01/2025, the officer acquired 32,000 and 26,619 American Depositary Shares (ADS) at $0.75 per ADS. The filing lists post‑transaction beneficial ownership of 32,000 and 26,619 ADS, held directly.
These ADSs represent restricted stock units (RSUs) that vest on January 1, 2026 and February 15, 2026. Each ADS represents 2,000 ordinary shares.
Akari Therapeutics (AKTX) disclosed a Form 4 showing its Interim CFO acquired 6,277 American Depositary Shares on October 22, 2025, reported as code A at $0.74 per ADS. Following the transaction, 6,277 ADS are beneficially owned with direct ownership.
The filing notes these ADSs represent restricted stock units (RSUs) that vest on October 31, 2025. Each ADS represents 2,000 Ordinary Shares of the company.
Akari Therapeutics (AKTX) reported an initial beneficial ownership filing on Form 3 for an officer serving as Interim CFO. The filing indicates no securities are beneficially owned, as stated in the remarks. The event date is 10/22/2025, and the form was filed by one reporting person. A Power of Attorney (Exhibit 24) is referenced for the signature authorization.
Akari Therapeutics (AKTX) appointed Kameel Farag as interim CFO, effective October 22, 2025, succeeding prior CFO Torsten Hombeck. Farag brings senior finance experience from Aspen Neuroscience, Ionis, and Amgen, and serves on the Biovie board.
The company entered a Consulting Agreement with Farag and KDF Ventures LLC. Through the end of 2025, compensation is $18,000 per month in cash plus $12,000 in RSUs, vesting monthly. From January 1, 2026 to February 15, 2026, fees increase to $27,000 cash plus $13,000 in RSUs, vesting monthly. The agreement runs to February 16, 2026 and can be extended month‑to‑month at the company’s discretion. In connection with certain capital raises, KDF Ventures may receive additional cash and RSU compensation based on a percentage of total gross proceeds, subject to maximum limits and timing conditions.
Akari Therapeutics (AKTX) launched a primary registered direct offering of 3,125,000 ADSs at $0.80 per ADS, for gross proceeds of $2.5 million. The deal is on a best efforts basis via Ladenburg Thalmann, with no minimum. The company estimates net proceeds of approximately $1.8 million after placement agent fees and offering expenses, and expects delivery around October 16, 2025, subject to customary closing conditions.
In a concurrent private placement, Akari is issuing 3,125,000 Series E warrants and 3,125,000 Series F warrants, each exercisable for one ADS at $0.98 per ADS, beginning on the Shareholder Approval Date. These warrants and the ADSs issuable upon exercise are not registered here. The company plans to file a resale registration statement within 30 days after closing. Akari intends to use net proceeds for working capital, general corporate purposes, and continued R&D, including generating differentiated data on its novel ADC payload. The company states that, together with existing cash, funds are expected to meet capital needs into December 2025. The filing notes expected immediate and substantial dilution of approximately $1.44 per ADS to new purchasers.
Akari Therapeutics entered a registered direct offering of 3,125,000 ADSs at $0.80 per ADS, for expected $2.5 million in aggregate gross proceeds, subject to customary closing conditions. The ADS sale is a takedown from Akari’s effective Form F-3 shelf.
Concurrently, the company issued Series E and Series F warrants in a private placement, each exercisable for up to 3,125,000 ADSs at an exercise price of $0.98 per ADS. Both series become exercisable on the effective date of shareholder approval; Series E carries a five-year term and Series F a thirty‑month term. Akari will file a resale registration for the warrant shares within 30 days of closing and will call a shareholder meeting within 60 days to seek approval, then every 40 days until obtained or the warrants expire.
Ladenburg Thalmann is placement agent, entitled to a 7.2% fee, 0.5% management fee, up to $75,000 expense allowance, and Placement Agent Warrants to purchase 125,000 ADSs at $1.00 per ADS (five‑year term). The purchase agreement includes a 30‑day issuance/registration standstill and a one‑year prohibition on variable rate transactions, in each case with customary exceptions.
Akari Therapeutics (AKTX) furnished an 8-K announcing a $2.5 million registered direct offering. The company disclosed, under Item 7.01 (Regulation FD), that it issued a press release titled “Akari Therapeutics Announces $2.5 Million Registered Direct Offering.” The press release is included as an exhibit and the furnished information is not deemed filed under the Exchange Act.
Akari’s American Depositary Shares, each representing 2,000 ordinary shares, trade on Nasdaq under the symbol AKTX. The filing lists the date of the earliest event as October 15, 2025.
Akari Therapeutics, Plc reports that it has completed its previously disclosed August 2025 unsecured promissory notes financing. The company had agreed to sell notes with a 20% original issue discount for an aggregate purchase price of $3 million, resulting in a total principal amount of approximately $3.8 million.
On September 26, 2025, Akari closed the final tranche of this private placement, issuing $312,500 in aggregate principal amount of August 2025 Notes for a purchase price of $250,000. After this closing, the full approximate $3.8 million principal amount of August 2025 Notes has been issued to investors.